APO Research
Talk to an analyst

APO RESEARCH · REPORT

Resistant Pseudomonas Aeruginosa Infections Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Resistant Pseudomonas Aeruginosa Infections Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025188 pages

Choose your research edition.

Industry ResearchResistant Pseudomonas Aeruginosa Infections Drugs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Resistant Pseudomonas Aeruginosa Infections Drugs Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Resistant Pseudomonas Aeruginosa Infections Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Resistant Pseudomonas Aeruginosa Infections Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Resistant Pseudomonas Aeruginosa Infections Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Resistant Pseudomonas Aeruginosa Infections Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Resistant Pseudomonas Aeruginosa Infections Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Resistant Pseudomonas Aeruginosa Infections Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Resistant Pseudomonas Aeruginosa Infections Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Resistant Pseudomonas Aeruginosa Infections Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs include Achaogen Inc, AmpliPhi Biosciences Corp, Biolytics Pharma, ContraFect Corp, Inhibrx LP, LegoChem Biosciences Inc, Melinta Therapeutics Inc, Shionogi & Co Ltd and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Resistant Pseudomonas Aeruginosa Infections Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Resistant Pseudomonas Aeruginosa Infections Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Resistant Pseudomonas Aeruginosa Infections Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Resistant Pseudomonas Aeruginosa Infections Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Company

Achaogen Inc

AmpliPhi Biosciences Corp

Biolytics Pharma

ContraFect Corp

Inhibrx LP

LegoChem Biosciences Inc

Melinta Therapeutics Inc

Shionogi & Co Ltd

Novartis AG

Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Type

Cephalosporin

Lactam Drugs

Semi-Synthetic Penicillin

Others

Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Application

Hospital

Clinic

Home Care

Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Resistant Pseudomonas Aeruginosa Infections Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Resistant Pseudomonas Aeruginosa Infections Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Resistant Pseudomonas Aeruginosa Infections Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Resistant Pseudomonas Aeruginosa Infections Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Resistant Pseudomonas Aeruginosa Infections Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Resistant Pseudomonas Aeruginosa Infections Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Resistant Pseudomonas Aeruginosa Infections Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Resistant Pseudomonas Aeruginosa Infections Drugs Industry Trends Table 2. Resistant Pseudomonas Aeruginosa Infections Drugs Industry Drivers Table 3. Resistant Pseudomonas Aeruginosa Infections Drugs Industry Opportunities and Challenges Table 4. Resistant Pseudomonas Aeruginosa Infections Drugs Industry Restraints Table 5. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Manufacturers Table 9. Global Resistant Pseudomonas Aeruginosa Infections Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Resistant Pseudomonas Aeruginosa Infections Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Resistant Pseudomonas Aeruginosa Infections Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers, Product Type & Application Table 13. Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Resistant Pseudomonas Aeruginosa Infections Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Cephalosporin Table 17. Major Manufacturers of Lactam Drugs Table 18. Major Manufacturers of Semi-Synthetic Penicillin Table 19. Major Manufacturers of Others Table 20. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2026) & (K Units) Table 22. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2027-2032) & (K Units) Table 23. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2021-2026) Table 24. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2027-2032) Table 25. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021-2026) & (K Units) Table 27. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2027-2032) & (K Units) Table 28. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Home Care Table 33. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2026) & (K Units) Table 35. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2027-2032) & (K Units) Table 36. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2021-2026) Table 37. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2027-2032) Table 38. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021-2026) & (K Units) Table 40. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2027-2032) & (K Units) Table 41. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2021-2026) Table 42. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2027-2032) Table 43. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2021-2026) Table 46. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2026) & (K Units) Table 50. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2027-2032) & (K Units) Table 51. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2026) & (K Units) Table 53. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2027-2032) & (K Units) Table 60. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2021-2026) Table 64. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2027-2032) Table 65. Achaogen Inc Company Information Table 66. Achaogen Inc Business Overview Table 67. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 69. Achaogen Inc Recent Development Table 70. AmpliPhi Biosciences Corp Company Information Table 71. AmpliPhi Biosciences Corp Business Overview Table 72. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 74. AmpliPhi Biosciences Corp Recent Development Table 75. Biolytics Pharma Company Information Table 76. Biolytics Pharma Business Overview Table 77. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 79. Biolytics Pharma Recent Development Table 80. ContraFect Corp Company Information Table 81. ContraFect Corp Business Overview Table 82. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 84. ContraFect Corp Recent Development Table 85. Inhibrx LP Company Information Table 86. Inhibrx LP Business Overview Table 87. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 89. Inhibrx LP Recent Development Table 90. LegoChem Biosciences Inc Company Information Table 91. LegoChem Biosciences Inc Business Overview Table 92. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 94. LegoChem Biosciences Inc Recent Development Table 95. Melinta Therapeutics Inc Company Information Table 96. Melinta Therapeutics Inc Business Overview Table 97. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 99. Melinta Therapeutics Inc Recent Development Table 100. Shionogi & Co Ltd Company Information Table 101. Shionogi & Co Ltd Business Overview Table 102. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 104. Shionogi & Co Ltd Recent Development Table 105. Novartis AG Company Information Table 106. Novartis AG Business Overview Table 107. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 109. Novartis AG Recent Development Table 110. Key Raw Materials Table 111. Raw Materials Key Suppliers Table 112. Resistant Pseudomonas Aeruginosa Infections Drugs Distributors List Table 113. Resistant Pseudomonas Aeruginosa Infections Drugs Customers List Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Resistant Pseudomonas Aeruginosa Infections Drugs Product Image Figure 2. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (2021-2032) & (K Units) Figure 5. Global Resistant Pseudomonas Aeruginosa Infections Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Resistant Pseudomonas Aeruginosa Infections Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Cephalosporin Image Figure 9. Lactam Drugs Image Figure 10. Semi-Synthetic Penicillin Image Figure 11. Others Image Figure 12. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2021-2032) Figure 15. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Home Care Image Figure 21. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2021-2032) Figure 24. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2021-2032) Figure 41. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Resistant Pseudomonas Aeruginosa Infections Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Resistant Pseudomonas Aeruginosa Infections Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Cephalosporin
  • Lactam Drugs
  • Semi-Synthetic Penicillin
  • Others
Applications
  • Hospital
  • Clinic
  • Home Care
Companies covered
  • Achaogen Inc
  • AmpliPhi Biosciences Corp
  • Biolytics Pharma
  • ContraFect Corp
  • Inhibrx LP
  • LegoChem Biosciences Inc
  • Melinta Therapeutics Inc
  • Shionogi & Co Ltd
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Dynamics
  1. 2.1 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Trends
  2. 2.2 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Drivers
  3. 2.3 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Opportunities and Challenges
  4. 2.4 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Restraints
3 Resistant Pseudomonas Aeruginosa Infections Drugs Market by Manufacturers
  1. 3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Resistant Pseudomonas Aeruginosa Infections Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Resistant Pseudomonas Aeruginosa Infections Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Resistant Pseudomonas Aeruginosa Infections Drugs Tier 1, Tier 2, and Tier 3
4 Resistant Pseudomonas Aeruginosa Infections Drugs Market by Type
  1. 4.1 Resistant Pseudomonas Aeruginosa Infections Drugs Type Introduction
  2. 4.1.1 Cephalosporin
  3. 4.1.2 Lactam Drugs
  4. 4.1.3 Semi-Synthetic Penicillin
  5. 4.1.4 Others
  6. 4.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type
  7. 4.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2032)
  9. 4.2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2021-2032)
  10. 4.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type
  11. 4.3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021-2032)
  13. 4.3.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2021-2032)
5 Resistant Pseudomonas Aeruginosa Infections Drugs Market by Application
  1. 5.1 Resistant Pseudomonas Aeruginosa Infections Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Home Care
  5. 5.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application
  6. 5.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application
  10. 5.3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2021-2032)
6 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region
  1. 6.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region
  1. 7.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region
  2. 7.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032)
  8. 7.2.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Achaogen Inc
  2. 8.1.1 Achaogen Inc Company Information
  3. 8.1.2 Achaogen Inc Business Overview
  4. 8.1.3 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  6. 8.1.5 Achaogen Inc Recent Developments
  7. 8.2 AmpliPhi Biosciences Corp
  8. 8.2.1 AmpliPhi Biosciences Corp Company Information
  9. 8.2.2 AmpliPhi Biosciences Corp Business Overview
  10. 8.2.3 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  12. 8.2.5 AmpliPhi Biosciences Corp Recent Developments
  13. 8.3 Biolytics Pharma
  14. 8.3.1 Biolytics Pharma Company Information
  15. 8.3.2 Biolytics Pharma Business Overview
  16. 8.3.3 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  18. 8.3.5 Biolytics Pharma Recent Developments
  19. 8.4 ContraFect Corp
  20. 8.4.1 ContraFect Corp Company Information
  21. 8.4.2 ContraFect Corp Business Overview
  22. 8.4.3 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  24. 8.4.5 ContraFect Corp Recent Developments
  25. 8.5 Inhibrx LP
  26. 8.5.1 Inhibrx LP Company Information
  27. 8.5.2 Inhibrx LP Business Overview
  28. 8.5.3 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  30. 8.5.5 Inhibrx LP Recent Developments
  31. 8.6 LegoChem Biosciences Inc
  32. 8.6.1 LegoChem Biosciences Inc Company Information
  33. 8.6.2 LegoChem Biosciences Inc Business Overview
  34. 8.6.3 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  36. 8.6.5 LegoChem Biosciences Inc Recent Developments
  37. 8.7 Melinta Therapeutics Inc
  38. 8.7.1 Melinta Therapeutics Inc Company Information
  39. 8.7.2 Melinta Therapeutics Inc Business Overview
  40. 8.7.3 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  42. 8.7.5 Melinta Therapeutics Inc Recent Developments
  43. 8.8 Shionogi & Co Ltd
  44. 8.8.1 Shionogi & Co Ltd Company Information
  45. 8.8.2 Shionogi & Co Ltd Business Overview
  46. 8.8.3 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  48. 8.8.5 Shionogi & Co Ltd Recent Developments
  49. 8.9 Novartis AG
  50. 8.9.1 Novartis AG Company Information
  51. 8.9.2 Novartis AG Business Overview
  52. 8.9.3 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  54. 8.9.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Resistant Pseudomonas Aeruginosa Infections Drugs Value Chain Analysis
  2. 9.1.1 Resistant Pseudomonas Aeruginosa Infections Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Resistant Pseudomonas Aeruginosa Infections Drugs Production Mode & Process
  6. 9.2 Resistant Pseudomonas Aeruginosa Infections Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Resistant Pseudomonas Aeruginosa Infections Drugs Distributors
  9. 9.2.3 Resistant Pseudomonas Aeruginosa Infections Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst